» Articles » PMID: 21368897

Risk Assessment in Skin Gene Therapy: Viral-cellular Fusion Transcripts Generated by Proviral Transcriptional Read-through in Keratinocytes Transduced with Self-inactivating Lentiviral Vectors

Overview
Journal Gene Ther
Date 2011 Mar 4
PMID 21368897
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Cutaneous gene therapy can be envisioned through the use of keratinocyte stem cell clones in which retroviral genotoxic risks can be pre-assessed. While transactivation of cellular genes by the retroviral long terminal repeat enhancer has been proven in experimental and clinical settings, the formation of chimeric viral-cellular transcripts originated by the inefficient termination (read-through) of retroviral transcripts remains to be studied in depth. We now demonstrate the widespread presence of viral-cellular fusion transcripts derived from integrated proviruses in keratinocytes transduced with self-inactivating (SIN) retroviral vectors. We have detected high molecular weight RNAs in northern blot analysis of retroviral vector expression in individual cell clones. Characterization of some of these transcripts revealed that they originate from genes located at the proviral integration sites. One class of transcripts corresponds to fusions of the viral vectors with intronic sequences, terminating at cryptic polyadenylation sites located in introns. A second class comprises fusion transcripts with coding sequences of genes at the integration sites. These are generated through splicing from a cryptic, not previously described donor site in the lentiviral vectors to exons of cellular genes, and have the potential to encode unintended open reading frames, although they are downregulated by cellular mechanisms. Our data contribute to a better understanding of the impact of SIN lentiviral vector integration on cellular gene transcription, and will be helpful in improving the design of this type of vectors.

Citing Articles

An optimized protocol for quality control of gene therapy vectors using nanopore direct RNA sequencing.

Zeglinski K, Montellese C, Ritchie M, Alhamdoosh M, Vonarburg C, Bowden R Genome Res. 2024; 34(11):1966-1975.

PMID: 39467647 PMC: 11610601. DOI: 10.1101/gr.279405.124.


Mechanisms and Delivery of tRNA Therapeutics.

Ward C, Beharry A, Tennakoon R, Rozik P, Wilhelm S, Heinemann I Chem Rev. 2024; 124(12):7976-8008.

PMID: 38801719 PMC: 11212642. DOI: 10.1021/acs.chemrev.4c00142.


Delivery of gene editing therapeutics.

Kevadiya B, Islam F, Deol P, Zaman L, Mosselhy D, Ashaduzzaman M Nanomedicine. 2023; 54:102711.

PMID: 37813236 PMC: 10843524. DOI: 10.1016/j.nano.2023.102711.


Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects.

Celdran J, Humphreys L, Gonzalez D, Soto-Sanchez C, Martinez-Navarrete G, Maldonado I Pharmaceutics. 2023; 15(7).

PMID: 37514046 PMC: 10384779. DOI: 10.3390/pharmaceutics15071860.


Correcting inborn errors of immunity: From viral mediated gene addition to gene editing.

Castiello M, Ferrari S, Villa A Semin Immunol. 2023; 66:101731.

PMID: 36863140 PMC: 10109147. DOI: 10.1016/j.smim.2023.101731.